SkinBioTherapeutics launches probiotic supplement to target psoriasis

By Nikki Hancocks

- Last updated on GMT

Copyright of SkinBiotherapeutics
Copyright of SkinBiotherapeutics

Related tags skin health Beauty from within Probiotics microbiome Gut health

SkinBioTherapeutics has announced its first commercial product launch with a probiotic supplement developed to target psoriasis.

The UK-based skin-health focused life science company will be launching the new supplement in Q4 of this year, under the brand AxisBiotix. Targeting the gut-skin axis​, the new supplement will contain Bifidobacterium animalis, Lactobacillus brevis, Lactobacillus reuteri, ​and Lactococcus lactis ​and will come in a powder format, to be mixed with water.

The launch comes off the back of a successful study, named BRIGHT. The study involved 267 participants, with 177 identifying as having psoriasis and other participants presenting a range of other skin conditions including acne and eczema.

Participants were given the product to be taken daily for 56 days, mixed with water. Using an app, they were able to share descriptions and photos of their conditions throughout the study as well as changes in their quality of life.

Stuart Ashman, CEO of SkinBioTherapeutics, says “We are delighted with the results of the study… 76% of all participants that completed the study saw a significant reduction in itchiness, 75% saw a reduction in redness, 73% saw a reduction in irritability and finally, 65% saw a reduction in flaky patches.”

Psoriosis is an auto-immune condition for which there is no cure and it impacts 2-3% of the population – up to 125m people worldwide (National Psoriasis Foundation 2020).

The condition is usually treated on a reactive basis, after condition occur, using topical creams. This new product gives patients an opportunity to take a proactive/preventative approach.

Beyond the skin symptoms, the study also asked particpants about other areas of their wellbeing throughout the study and the results indicate the reduction in skin symptoms corresponded with improvements in energy levels, sleep quality, and mood.

Dr Jonathan Sheffield, senior medical advisor to SkinBioTherapeutics, adds “Psoriasis is not just a disease of the skin. It causes wide-spread systemic effects on the joints etc so anything that can reduce the symptoms would be a major advance in the treatment of psoriasis.

“The outcomes reported by the participants in the BRIGHT study are incredibly promising, with 70% of the people seeing a major improvement in symptoms this is really exciting for the future of SkinBiotics.”

The product will initially launch to the UK and US markets. The company is currently encouraging pre-registration for the product, on a subscription basis.

Related news

Show more

Related products

show more

A Taste of Metabolic Health

A Taste of Metabolic Health

Content provided by ADM | 07-Sep-2023 | Case Study

Are you ready to transform the way consumers support their metabolic health? Our latest case study featuring ADM’s propriety, awarding winning strain Bifidobacterium...

Uncover the Potential of Kombucha in APAC

Uncover the Potential of Kombucha in APAC

Content provided by Lumina Intelligence | 02-Aug-2023 | White Paper

The paper explores consumer engagement in the APAC region concerning Kombucha products and probiotic juices, along with the factors that drive this engagement.

BioCell Collagen Science Review

BioCell Collagen Science Review

Content provided by BioCell Technology, LLC | 13-Jul-2023 | White Paper

BioCell Collagen® is a clinically studied dietary supplement ingredient composed of naturally-occurring hydrolyzed collagen type II peptides, chondroitin...

Related suppliers

Follow us


View more